Akrotome Co-Founder, Dr. Jim Basilion, traveled to Europe to make invited presentations in November, 2018. Dr. Basilion delivered papers focused on the use of molecular probes for guided, precision surgery to the European Society of Molecular Imaging, the World...
Akrotome CEO accepts invitation to be a reviewer for NCI Bridge Award applications. Dr. Brian Straight, President and CEO of Akrotome, has accepted an invitation to be a reviewer for the National Cancer Institute’s Bridge Award Program, which seeks to provide...
May 15, 2017—Akrotome Co-Founder Dr. James Basilion attended the World Molecular Imaging Congress/National Cancer Institute workshop in Washington DC. The workshop included participants from FDA and the Centers for Medicare & Medicaid Services (CMS). Focused on...
June 1, 2017. Akrotome Imaging announces the launch of its FIRE probe technology. FIRE (Fluorescent Image Resection Enhancement) is a family for quenched, activity-based (QAB) and quenched substrate-based (QSB) probes with unparalleled performance, precision, and...
Akrotome receives grant for the commercialization of a topical probe for margin determination in skin cancers Akrotome Imaging has received a $1.77M SBIR Phase II grant to assist in the clinical translation of its FIRE™ probe for margin assessment in skin cancer. In...
